Emerging drugs for the treatment of gastroparesis

作者: William L Hasler

DOI: 10.1517/14728214.2014.899353

关键词:

摘要: Introduction: Gastroparesis presents with symptoms of gastric retention findings delayed emptying on diagnostic testing. Manifestations gastroparesis are disabling in severe cases and lead to significant health resource utilization. Current therapies often ineffective, may exhibit tolerance chronic administration or produce prominent side effects large patient subsets. Areas covered: This review assessed literature drugs theoretical efficacy including medications that accelerate emptying, reduce nausea vomiting, act as neuromodulators sensitivity. Numerous agents diverse actions modify sensorimotor function animal models; however, few controlled testing gastroparesis. Prokinetic promise for this condition include investigational serotonin 5-HT4 agonists, motilin dopamine D2 antagonists, ghrelin agonists an agent combined muscarinic antagonist ...

参考文章(108)
Archana Kedar, Yana Nikitina, Evelyn Martin, Vetta Vedanarayanan, Thomas L. Abell, Tu2107 Immunomodulation for Treatment of Drug and Device Refractory Gastroparesis: An Open Label Pilot Study of GAD65 Positive Patients Gastroenterology. ,vol. 144, pp. S- 931 ,(2013) , 10.1016/S0016-5085(13)63462-9
Per M. Hellström, Jan F. Tack, Kimberley E. Stephens, Matthew E. Barton, Lakshmi S. Vasist, Duncan B. Richards, Pauline M. Williams, David H. Alpers, George E. Dukes, A Double-Blind, Randomized Placebo-Controlled Phase II Study of the Pharmacodynamics, Safety/Tolerability, and Pharmacokinetics of Single Doses of the Motilin Agonist GSK962040, in Patients With Type I Diabetes Mellitus (T1DM) and Gastroparesis Gastroenterology. ,vol. 140, pp. S- 813 ,(2011) , 10.1016/S0016-5085(11)63366-0
Boudewijn F. Kessing, Andreas J. Smout, Roelof J. Bennink, Noémie Kraaijpoel, Jac. Oors, Albert J. Bredenoord, 745 Prucalopride Decreases Esophageal Acid Exposure and Accelerates Gastric Emptying in Healthy Subjects Gastroenterology. ,vol. 144, ,(2013) , 10.1016/S0016-5085(13)60485-0
Fermin Mearin, Michael Camilleri, Juan-R. Malagelada, Pyloric dysfunction in diabetics with recurrent nausea and vomiting Gastroenterology. ,vol. 90, pp. 1919- 1925 ,(1986) , 10.1016/0016-5085(86)90262-3
L. Wang, N. P. Murphy, A. Stengel, M. Goebel-Stengel, D. H. St Pierre, N. T. Maidment, Y. Taché, Ghrelin prevents levodopa‐induced inhibition of gastric emptying and increases circulating levodopa in fasted rats Neurogastroenterology and Motility. ,vol. 24, ,(2012) , 10.1111/J.1365-2982.2012.01904.X
J. M. Wo, N. Ejskjaer, P. M. Hellström, R. A. Malik, J. C. Pezzullo, L. Shaughnessy, P. Charlton, G. Kosutic, R. W. McCallum, Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data. Alimentary Pharmacology & Therapeutics. ,vol. 33, pp. 679- 688 ,(2011) , 10.1111/J.1365-2036.2010.04567.X
N. Ejskjaer, J. M. Wo, T. Esfandyari, M. Mazen Jamal, G. Dimcevski, L. Tarnow, R. A. Malik, P. M. Hellström, E. Mondou, J. Quinn, F. Rousseau, R. W. McCallum, A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis Neurogastroenterology and Motility. ,vol. 25, ,(2013) , 10.1111/NMO.12064
John Broad, Gareth J Sanger, The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. British Journal of Pharmacology. ,vol. 168, pp. 1859- 1867 ,(2013) , 10.1111/BPH.12077